Biologics Inc., a McKesson Specialty Health oncology pharmacy services company, has been chosen by Tesaro Inc. to provide its new drug.
Tesaro chose Biologics to be the specialty pharmacy provider for ZEJULA, which is meant for adults with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, and are in partial or complete response to chemo that is platinum-based. It was approved by the FDA on March 27, making it a brand new medication.
"This is a very exciting advancement for the treatment of this patient population and we are thrilled to be part of the distribution network," Brandon Tom, vice president of Biopharma Services, McKesson Specialty Health, said.
The American Cancer Society states that there are more than 22,000 women who will be diagnosed with ovarian cancer this year, and until recently, there have not been many solutions for such situations.
The clinical trial results for ZEJULA has shown that the risk of serious progression or death has been reduced by 74 percent in those with germline BRCA mutations. Those without the germline BRCA still can expect 55 percent reduction in risk of death or progression.
Biologics is unique in its multidisciplinary approach to customer care, which includes financial advising, personalized care plans and more.
Alerts Sign-up